

November 11, 2024

To,  
BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Scrip Code: 531015**

**Subject: Submission of Unaudited Standalone Financial Results along with Auditors' Report for the quarter ended 30<sup>th</sup> September, 2024**

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Un-audited Standalone Financial Results along with Limited Review Report of the Statutory Auditors of the company, PPKG & Co Chartered Accountants for the quarter and Half Year ended 30th September, 2024.

The Financial Results are also available on the website of the Company at [www.venmaxdrugs.com](http://www.venmaxdrugs.com) and on the website of BSE [www.bseindia.com](http://www.bseindia.com).

The Board Meeting commenced at 02:30 PM and concluded at 03:25 PM.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

**Nooka Krishnaiah**  
**Managing Director**  
**DIN: 07279009**

Statement of Financial Results for the Quarter and Half Year ended 30th September 2024

(RS. IN LAKHS)

	Particulars	Quarter ended			Half year ended		Year Ended
		30/09/2024 (unaudited)	30/06/2024 (unaudited)	30/09/2023 (unaudited)	30/09/2024 (unaudited)	30/09/2023 (unaudited)	31/03/2024 (Audited)
-	<b>Income</b>						
I	Revenue from operations	17.13	10.40	-	27.53		
II	Other income	-	3.00		3.00	5.00	19.86
	<b>Total Revenue (I+II)</b>	<b>17.13</b>	<b>13.40</b>	<b>-</b>	<b>30.53</b>	<b>5.00</b>	<b>19.86</b>
II	<b>Expenses</b>						
	Cost of materials consumed			-	-		-
	Purchases of Stock-in-Trade	20.00	10.27		30.27		
	Change of Inventory	-	-	-	-	-	-
	Employee benefits expense	0.35	-	0.60	0.35	1.20	2.25
	Finance costs	0.08	-	-	0.08	-	-
	Depreciation and amortization expense	0.16	0.16	0.18	0.32	0.36	0.72
	Other expenses	26.97	1.90	2.05	28.87	4.47	8.20
	<b>Total expenses</b>	<b>47.56</b>	<b>12.33</b>	<b>2.83</b>	<b>59.89</b>	<b>6.03</b>	<b>11.17</b>
III	Profit before Exceptional items and tax	(30.43)	1.07	(2.83)	(29.35)	(1.03)	8.69
	Exceptional Items						
	<b>Profit / (Loss) before tax</b>	<b>(30.43)</b>	<b>1.07</b>	<b>(2.83)</b>	<b>(29.35)</b>	<b>(1.03)</b>	<b>8.69</b>
IV	Tax expense:						
	Current tax		-		-		2.24
	Deferred tax	0.015	(0.005)		0.01	-	(0.004)
	Profit/(loss) for the period from continuing operations	<b>0.02</b>	<b>0.01</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>2.24</b>
	Profit/(loss) from discontinued operations						
	Tax expense of discontinued operations						
	Profit/(loss) from Discontinued operations (After tax)						
V	<b>Profit/(loss) for the year</b>	<b>(30.44)</b>	<b>1.08</b>	<b>(2.83)</b>	<b>(29.36)</b>	<b>(1.03)</b>	<b>6.45</b>
	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or Loss						

	(ii) Income tax relating to items that will not be reclassified to Profit or Loss						
	B (i) Items that will be reclassified to Profit or Loss						
	(ii) Income tax relating to items that will be reclassified to Profit or Loss						
	Total Comprehensive Incoe for the period (Comprising Profit / (Loss)) and Other Comprehensive Income for the period)						
VI	Earnings per Equity Share - Basic and Diluted	(0.58)	0.02	(0.054)	(0.56)	(0.020)	0.12

**Notes to Accounts:**

1. The above unaudited financial results of VENMAX DRUGS AND PHARMACEUTICALS LIMITED for the Quarter ended 30th September 2024 as reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 11th November, 2024. The Statutory Auditors of the Company have carried out a Limited Review on standalone financial results and expressed an unmodified conclusion thereon.
2. The Financial results have been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standard) Rules, 20105 (Ind AS), and other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India (SEBI).
3. The Company operates in single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
4. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.

Place: Hyderabad  
Date: 11th November 2024

For Venmax Drugs and Pharmaceuticals Limited

Nooka Krishnaiah  
Managing Director  
DIN: 07279009

Statement of Assets and Liabilities as at 30th September 2024

(RS. IN LAKHS)

Particulars	Notes	As at 30 September 2024, Unaudited	As at 31 March 2024, Audited
<b>I. ASSETS</b>			
(1) Non Current Assets			
(a) Property, Plant and Equipment	3	4.27	4.50
(b) Capital Work-In-Progress			
(c) Intangible Assets	4	1.98	2.08
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
<b>Non-Current Assets</b>		<b>6.25</b>	<b>6.58</b>
(2) Current Assets			
(a) Inventories			
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	32.49	0.00
(iii) Cash and Cash Equivalents	6	0.80	0.25
(iv) Short Term Loans and Advances			
(c) Other Current Assets	7	2.51	1.31
<b>Current Assets</b>		<b>35.81</b>	<b>1.56</b>
<b>Total Assets</b>		<b>42.06</b>	<b>8.14</b>
<b>I. EQUITY AND LIABILITIES</b>			
(1) Equity			
(a) Share Capital	8	523.89	523.89
(b) Other Equity	9	-618.25	-588.90
(c) Share warrants application money pending allotment			
<b>Equity</b>		<b>-94.36</b>	<b>-65.01</b>
(2) Non Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings			
(b) Provisions			
(c) Deferred Tax Liabilities (Net)	10	0.45	0.46
(d) Other Non-current Liabilities			
<b>Non-Current Liabilities</b>		<b>0.45</b>	<b>0.46</b>
(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings	11	35.21	35.21
- Other Financial Liabilities	12	10.81	10.81
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	13	44.52	10.34
(b) Short Term Provisions	14	2.24	2.24
(c) Other Current Liabilities	15	43.18	14.08
<b>Current Liabilities</b>		<b>135.97</b>	<b>72.69</b>
<b>Total Liabilities</b>		<b>42.06</b>	<b>8.14</b>

Place: Hyderabad  
Date: 11th November 2024

For Venmax Drugs and Pharmaceuticals Limited

Nooka Krishnaiah  
Managing Director  
DIN: 07279009

Cash Flow Statement for the Half Year ended 30th September 2024

Rs. In Lakhs

PARTICULARS	As at September 30, 2024	As at Mar 31, 2024
	UnAudited	Audited
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit as per Profit & Loss A/c	-29.35	8.69
Adjustment for:		
Depreciation	0.32	0.72
Other comprehensive income	-	-
<b>Net Operating Profit Before Working Capital</b>	<b>-29.03</b>	<b>9.41</b>
Changes		
Adjustment for :		
Trade & Other Receivables	-32.49	3.64
Changes in inventory	-	-
Other Current Assets	-1.20	8.9
Trade Payables	34.18	-22.5
Other Financial liabilities	0.00	0.0
Other current liabilities	29.10	2.02
Provisions	0.00	1.06
<b>Net Cash from Operating Activities</b>	<b>0.55</b>	<b>2.48</b>
Direct taxes paid	0	2.26
<b>Net Cash from Operating Activities</b>	<b>0.55</b>	<b>0.22</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	-	-
<b>Net Cash from Investing Activities</b>	<b>-</b>	<b>-</b>
<b>C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
From Bank Borrowings		
Proceeds from long/short term borrowings	-	0
<b>Net Cash from Financing Activities</b>	<b>-</b>	<b>0</b>
Net Increase in Cash & Cash Equivalents	0.55	0.22
Add : Opening Cash & Cash Equivalents	0.25	0.03
<b>Cash and Cash equivalents at the end of the year</b>	<b>0.80</b>	<b>0.25</b>

Place: Hyderabad  
Date: 11th November 2024

For Venmax Drugs and Pharmaceuticals Limited

Nooka Krishnaiah  
Managing Director  
DIN: 07279009

**Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors,  
Venmax Drugs and Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter and six months ended September 30, 2024 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO  
Chartered Accountants  
FRN: 0009655S

*Giridhari Lal Toshniwal*  
GIRIDHARI LAL TOSHNIWAL

(Partner)  
M.No-205140



Udin No: 24205140BKAL03516

Place: Hyderabad  
Date: 11/11/2024